David Jacob Fogelman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Palsy | 2 | 2023 | 481 | 0.290 |
Why?
|
| Drugs, Investigational | 1 | 2008 | 211 | 0.270 |
Why?
|
| BRCA2 Protein | 1 | 2011 | 802 | 0.260 |
Why?
|
| Benzamides | 1 | 2011 | 1376 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 5 | 2011 | 5454 | 0.240 |
Why?
|
| Adenocarcinoma | 5 | 2011 | 6363 | 0.200 |
Why?
|
| Cryptorchidism | 1 | 2023 | 152 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 11859 | 0.180 |
Why?
|
| Deoxycytidine | 2 | 2007 | 886 | 0.180 |
Why?
|
| Brain Injuries | 1 | 2012 | 2062 | 0.180 |
Why?
|
| Exercise | 2 | 2012 | 5939 | 0.160 |
Why?
|
| Cognition Disorders | 1 | 2012 | 3966 | 0.150 |
Why?
|
| Colorectal Neoplasms | 4 | 2009 | 6961 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 9378 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 2897 | 0.100 |
Why?
|
| Organoplatinum Compounds | 2 | 2009 | 407 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2008 | 3546 | 0.090 |
Why?
|
| Postnatal Care | 1 | 2011 | 273 | 0.080 |
Why?
|
| Duodenal Neoplasms | 1 | 2008 | 114 | 0.070 |
Why?
|
| Hypertension, Portal | 1 | 2009 | 229 | 0.070 |
Why?
|
| Fluorouracil | 3 | 2008 | 1648 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2008 | 314 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2011 | 598 | 0.060 |
Why?
|
| Sports | 1 | 2011 | 699 | 0.060 |
Why?
|
| Hepatectomy | 1 | 2008 | 588 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 420 | 0.060 |
Why?
|
| Orchiopexy | 1 | 2023 | 21 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 21074 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2012 | 4133 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 329 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 1885 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 723 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2008 | 1216 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2023 | 159 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 895 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4352 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 2057 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 18076 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2006 | 1088 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2004 | 825 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2011 | 65219 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 1777 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2004 | 1475 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 2970 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2863 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2006 | 1163 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 8525 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2004 | 2249 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2023 | 1218 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 11200 | 0.030 |
Why?
|
| Liver | 1 | 2009 | 7559 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 6840 | 0.030 |
Why?
|
| Humans | 14 | 2023 | 766117 | 0.030 |
Why?
|
| Middle Aged | 9 | 2011 | 223083 | 0.030 |
Why?
|
| Depression | 1 | 2012 | 8230 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2004 | 10087 | 0.020 |
Why?
|
| Female | 10 | 2022 | 396233 | 0.020 |
Why?
|
| Animals | 3 | 2012 | 168800 | 0.020 |
Why?
|
| Survival Rate | 3 | 2010 | 12827 | 0.020 |
Why?
|
| Male | 10 | 2023 | 363935 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23605 | 0.020 |
Why?
|
| Aged | 8 | 2010 | 171219 | 0.020 |
Why?
|
| Prognosis | 2 | 2010 | 29912 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2008 | 94 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1695 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 598 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13635 | 0.020 |
Why?
|
| Child | 3 | 2023 | 80573 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 2469 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 27177 | 0.020 |
Why?
|
| Adult | 7 | 2010 | 223139 | 0.020 |
Why?
|
| Camptothecin | 1 | 2008 | 598 | 0.010 |
Why?
|
| Quinazolines | 1 | 2010 | 1366 | 0.010 |
Why?
|
| Taxoids | 1 | 2007 | 665 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2022 | 42511 | 0.010 |
Why?
|
| Sirolimus | 1 | 2010 | 1541 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 500 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2007 | 1754 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 13483 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2455 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8292 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2022 | 41684 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6506 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 88819 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4213 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 4887 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2006 | 2593 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 5695 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11035 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 59515 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 9237 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 9508 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 30233 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2008 | 81565 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2010 | 54812 | 0.000 |
Why?
|
| Infant | 1 | 2006 | 36427 | 0.000 |
Why?
|